interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Bupropion Hydrochloride; Dextromethorphan Hydrobromide

Generic competition · all medicines · read 12 November 2026

Is there a generic of Bupropion Hydrochloride; Dextromethorphan Hydrobromide, and who makes it?

Bupropion Hydrochloride; Dextromethorphan Hydrobromide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Bupropion Hydrochloride; Dextromethorphan Hydrobromide1 dosage-form group in the Orange Book
0generic makers listed
  1. Bupropion Hydrochloride; Dextromethorphan Hydrobromide appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Extended Release, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Auvelity. No generic is listed as marketed.

20202025203020352040204501brand 2022data datePatent 8569328 listed to expire 18 July 2032Patent 9968568 listed to expire 5 November 2034Patent 9168234 listed to expire 5 November 2034Patent 10080727 listed to expire 5 November 2034Patent 11590124 listed to expire 5 November 2034Patent 11291638 listed to expire 5 November 2034Patent 11007189 listed to expire 5 November 2034Patent 9700528 listed to expire 5 November 2034Patent 11253492 listed to expire 5 November 2034Patent 9861595 listed to expire 5 November 2034Patent 9700553 listed to expire 5 November 2034Patent 9486450 listed to expire 5 November 2034Patent 9370513 listed to expire 5 November 2034Patent 9375429 listed to expire 5 November 2034Patent 9314462 listed to expire 5 November 2034Patent 9457023 listed to expire 5 November 2034Patent 11207281 listed to expire 5 November 2034Patent 10092560 listed to expire 5 November 2034Patent 10780066 listed to expire 5 November 2034Patent 9198905 listed to expire 5 November 2034Patent 9205083 listed to expire 5 November 2034Patent 9707191 listed to expire 5 November 2034Patent 10058518 listed to expire 5 November 2034Patent 11571417 listed to expire 5 November 2034Patent 10105361 listed to expire 5 November 2034Patent 10251879 listed to expire 5 November 2034Patent 11285146 listed to expire 5 November 2034Patent 11273134 listed to expire 5 November 2034Patent 11273133 listed to expire 5 November 2034Patent 11298352 listed to expire 5 November 2034Patent 11344544 listed to expire 5 November 2034Patent 11426370 listed to expire 5 November 2034Patent 11382874 listed to expire 5 November 2034Patent 11234946 listed to expire 5 November 2034Patent 9763932 listed to expire 5 November 2034Patent 11617747 listed to expire 5 November 2034Patent 11285118 listed to expire 5 November 2034Patent 11419867 listed to expire 5 November 2034Patent 11291665 listed to expire 5 November 2034Patent 9421176 listed to expire 5 November 2034Exclusivity I-913 to 30 April 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 30 April 2029Exclusivity I-913 Auvelity
  • 18 July 2032Patent 8569328 drug product
  • 5 November 2034Patent 9968568
  • 5 November 2034Patent 9168234
  • 5 November 2034Patent 10080727
  • 5 November 2034Patent 11590124
  • 5 November 2034Patent 11291638
  • 5 November 2034Patent 11007189
  • 5 November 2034Patent 9700528

140 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.